Isavuconazole: a new extended spectrum triazole for invasive mold diseases.
Ananda-Rajah MR, Kontoyiannis D.
Future Microbiol · research support, non-u.s. gov't; journal article · DOI 10.2217/fmb.15.34 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för isavuconazole. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
8 träffarIsavuconazole: A New Option for the Management of Invasive Fungal Infections.
Pettit NN, Carver PL.
Ann Pharmacother · review; journal article · DOI 10.1177/1060028015581679Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
Pfaller MA, Rhomberg PR, Messer SA, Jones RN, Castanheira M.
Diagn Microbiol Infect Dis · research support, non-u.s. gov't; journal article · DOI 10.1016/j.diagmicrobio.2015.04.008Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model.
Seyedmousavi S, Brüggemann RJ, Meis JF, Melchers WJ, Verweij PE, Mouton JW.
Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.04907-14Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study.
Cornely OA, Böhme A, Schmitt-Hoffmann A, Ullmann AJ.
Antimicrob Agents Chemother · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1128/aac.04569-14A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis.
Viljoen J, Azie N, Schmitt-Hoffmann AH, Ghannoum M.
Antimicrob Agents Chemother · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1128/aac.04586-14Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases.
Seyedmousavi S, Verweij PE, Mouton JW.
Expert Rev Anti Infect Ther · review; journal article · DOI 10.1586/14787210.2015.990382Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method.
Espinel-Ingroff A, Chowdhary A, Gonzalez GM, Guinea J, Hagen F, Meis JF, Thompson GR, Turnidge J.
Antimicrob Agents Chemother · brief-report; multicenter study; journal article · DOI 10.1128/aac.04055-14